◎ Sugi Atlas

Atlas / Drug / Atezolizumab

Atezolizumab

drug
On this page

Also known as 0ine2sfd9eAtezolizumab-tqjcAnti-PD-L1Anti-PDL1MPDL-3280AMPDL3280ARG-7446RG7446Tecentriq

Summary

Atezolizumab (CHEMBL3707227) is an approved antibody (ATC L01FF05); indicated across 97 conditions including non-small cell lung carcinoma and breast carcinoma; with CIViC clinical evidence for 21 variant-indication associations (e.g. BRAF V600 in melanoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FF05
  • Indications: 97 conditions
  • Clinical trials: 690
  • Precision-oncology evidence (CIViC): 21 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3707227
NameAtezolizumab
TypeAntibody
Max phase4
ATCL01FF05

Also known as: 0ine2sfd9e, Atezolizumab, Atezolizumab-tqjc, Anti-PD-L1, Anti-PDL1, MPDL-3280A, MPDL3280A, RG-7446, RG7446, Tecentriq, ATEZOLIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

97 indications (12 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
breast carcinoma4MONDO:0004989EFO:0000305
neoplasm4MONDO:0005070EFO:0000616
small cell lung carcinoma4MONDO:0008433EFO:0000702
breast neoplasm4MONDO:0021100EFO:0003869
triple-negative breast carcinoma4MONDO:0005494EFO:0005537
urothelial carcinoma4MONDO:0040679EFO:0008528
lung neoplasm4MONDO:0021117MONDO:0008903
transitional cell carcinoma4MONDO:0006474EFO:1000601
benign urinary system neoplasm4MONDO:0004180MONDO:0004180
ovarian neoplasm3MONDO:0021068EFO:0003893
hepatocellular carcinoma3MONDO:0007256EFO:0000182
prostate adenocarcinoma3MONDO:0005082EFO:0000673
renal cell carcinoma3MONDO:0005086EFO:0000681
melanoma3MONDO:0005105EFO:0000756
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
cervical carcinoma3MONDO:0005131EFO:0001061
ovarian carcinoma3MONDO:0005140EFO:0001075
carcinoma of esophagus3MONDO:0019086EFO:0002916
colorectal carcinoma3MONDO:0024331EFO:1001951
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
cutaneous melanoma3MONDO:0005012EFO:0000389
metastatic melanoma3MONDO:0005191EFO:0002617
peritoneal neoplasm3MONDO:0006901EFO:1001100
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
fallopian tube neoplasm3MONDO:0021092MONDO:0002158
ovarian cancer3MONDO:0008170MONDO:0008170
endometrium neoplasm3MONDO:0021251MONDO:0011962
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
mesothelioma3MONDO:0005065EFO:0000588
papillary renal cell carcinoma3MONDO:0017884EFO:0000640
colorectal neoplasm3MONDO:0005335EFO:0004142
malignant peritoneal mesothelioma3MONDO:0005512EFO:0005567
fallopian tube carcinoma3MONDO:0006206EFO:1000251
uterine corpus cancer3MONDO:0006003EFO:0007532
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
Hodgkins lymphoma2MONDO:0004952EFO:0000183
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
gastric adenocarcinoma2MONDO:0005036EFO:0000503
glioblastoma2MONDO:0018177EFO:0000519
lymphoma2MONDO:0005062EFO:0000574
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
head and neck cancer2MONDO:0005627EFO:0006859
alveolar soft part sarcoma2MONDO:0011655EFO:0007143
rectal cancer2MONDO:0006519EFO:1000657
Sezary syndrome2MONDO:0017844EFO:1000785
mycosis fungoides2MONDO:0009691EFO:1001051
sarcoma2MONDO:0005089EFO:0000691
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
upper aerodigestive tract neoplasm2MONDO:0005398EFO:0004284
carcinoma2MONDO:0004993EFO:0000313
cholangiocarcinoma2MONDO:0019087EFO:0005221
uterine carcinosarcoma2MONDO:0006485EFO:1000613
anus neoplasm2MONDO:0003046MONDO:0001879
kidney cancer2MONDO:0002367MONDO:0002367
follicular lymphoma2MONDO:0018906MONDO:0018906
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
thyroid gland carcinoma2MONDO:0015075EFO:0002892
intrahepatic cholangiocarcinoma2MONDO:0003210EFO:1001961
osteosarcoma2MONDO:0009807EFO:0000637
colonic neoplasm2MONDO:0005401EFO:0004288
gallbladder carcinoma2MONDO:0003220EFO:1001956
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
lymphoid neoplasm2MONDO:0005157EFO:0001642
gastric neoplasm2MONDO:0021085MONDO:0001056
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
astrocytoma (excluding glioblastoma)2MONDO:0019781EFO:0000272
primary cutaneous T-cell non-Hodgkin lymphoma2MONDO:0000607EFO:0002913
head and neck neoplasm2MONDO:0005586EFO:0005950
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
oropharynx cancer2MONDO:0004608EFO:1001931
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
myelodysplastic syndrome1MONDO:0018881EFO:0000198
acute myeloid leukemia1MONDO:0018874EFO:0000222
plasma cell myeloma1MONDO:0009693EFO:0001378
gliosarcoma1MONDO:0016681EFO:1001465
chronic myeloid leukemia1MONDO:0011996EFO:0000339
glioma1MONDO:0021042MONDO:0100342
skin neoplasm1MONDO:0002531MONDO:0002898
idiopathic pulmonary fibrosis1MONDO:0800504EFO:0000768
rhabdomyosarcoma1MONDO:0005212EFO:0002918
paraganglioma1MONDO:0000448EFO:1000453
adenocarcinoma1MONDO:0004970MONDO:0003219

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 690.

Phase distribution

PhaseTrials
PHASE2296
PHASE1131
PHASE3104
PHASE1/PHASE2104
Not specified26
PHASE2/PHASE314
EARLY_PHASE19
PHASE46

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05185505PHASE4RECRUITINGAtezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05689671PHASE4ACTIVE_NOT_RECRUITINGPemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT07059494PHASE4RECRUITINGAtezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
NCT03285763PHASE4COMPLETEDA Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT05717400PHASE4TERMINATEDImproving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
NCT01810913PHASE2/PHASE3RECRUITINGTesting Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
NCT02486718PHASE3ACTIVE_NOT_RECRUITINGStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02839707PHASE2/PHASE3ACTIVE_NOT_RECRUITINGPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02912559PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02997228PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT03148418PHASE3ACTIVE_NOT_RECRUITINGA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03178552PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03281954PHASE3ACTIVE_NOT_RECRUITINGClinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03595592PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03755791PHASE3ACTIVE_NOT_RECRUITINGStudy of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03768063PHASE3ACTIVE_NOT_RECRUITINGA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03775265PHASE3ACTIVE_NOT_RECRUITINGChemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03799835PHASE3ACTIVE_NOT_RECRUITINGAtezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03811002PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03977194PHASE3ACTIVE_NOT_RECRUITINGAtezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT04102098PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04214262PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04402788PHASE2/PHASE3RECRUITINGTesting the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
NCT04446117PHASE3ACTIVE_NOT_RECRUITINGStudy of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04543617PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
NCT04637594PHASE3ACTIVE_NOT_RECRUITINGTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04649489PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
NCT04660344PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04665856PHASE3ACTIVE_NOT_RECRUITINGStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04712643PHASE3ACTIVE_NOT_RECRUITINGA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04770896PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04803994PHASE3RECRUITINGThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04873362PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT05047250PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05058651PHASE2/PHASE3RECRUITINGEvaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
NCT05063552PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05091567PHASE3ACTIVE_NOT_RECRUITINGA Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05112965PHASE3ACTIVE_NOT_RECRUITINGAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT05141721PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Clinical evidence (CIViC)

Variant × indication × effect (21 predictive associations from 22 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BRAF V600MelanomaSensitivity/ResponseAtezolizumab + Vemurafenib + CobimetinibCIViC AEID11238
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumabCIViC BEID1172 +1
BRAF V600E AND BRAF AmplificationEpithelial Ovarian CancerSensitivity/ResponseAtezolizumab + BevacizumabCIViC BEID9885
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Nivolumab + PembrolizumabCIViC BEID1167
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Pembrolizumab + Nivolumab + DurvalumabCIViC BEID4857
CD274 ExpressionBladder Urothelial CarcinomaSensitivity/ResponseAtezolizumabCIViC BEID9886
CTLA4 EXPRESSIONLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumabCIViC BEID5810
CX3CL1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumabCIViC BEID5812
EZH2 Y646NDiffuse Large B-cell LymphomaSensitivity/ResponseTazemetostat + AtezolizumabCIViC BEID11112
HLA-DRA EXPRESSIONSkin MelanomaSensitivity/ResponseNivolumab + Atezolizumab + PembrolizumabCIViC BEID985
KRAS MutationLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + NivolumabCIViC BEID4863
PBRM1 Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseAtezolizumab + DurvalumabCIViC BEID7537
TMB HighLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumabCIViC BEID12587
DNMT3A MutationCancerResistanceAtezolizumab + Nivolumab + PembrolizumabCIViC BEID2926
STK11 MutationLung AdenocarcinomaResistanceNivolumab + Atezolizumab + PembrolizumabCIViC BEID6441
MDM4 AmplificationCancerAdverse ResponseAtezolizumab + Nivolumab + PembrolizumabCIViC BEID2925
MDM4 EXPRESSIONCancerAdverse ResponseNivolumab + Atezolizumab + PembrolizumabCIViC BEID2917
JAK3 S61CLung AdenocarcinomaSensitivity/ResponseAtezolizumabCIViC CEID2979
JAK3 V722ILung AdenocarcinomaSensitivity/ResponseAtezolizumabCIViC CEID2978
ARID1A LossOvarian CancerSensitivity/ResponseAtezolizumab + Pembrolizumab + NivolumabCIViC DEID6399
CD274 v242Lung Non-small Cell CarcinomaResistanceDurvalumab + Atezolizumab + AvelumabCIViC EEID9695

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem